Research library
Metabolic & IncretinMaturing human RCT base
RETA
Retatrutide, Triple incretin receptor agonist
A once weekly triple agonist of the GLP-1, GIP, and glucagon receptors, the glucagon arm distinguishing it from dual agonists by raising energy expenditure.
Shop this peptide
GLP-1/GIP/GCG
~28%
Phase 3
How Retatrutide works
A single molecule hitting three metabolic receptors at once. The added glucagon arm raises energy burn on top of the appetite control of GLP-1/GIP, driving the largest trial weight losses yet.
Retatrutide
GLP-1 and GIP and GCG
Satiety + insulin + burn
Weight & glucose ↓
Research applications
Obesity
Weight reduction
Type 2 diabetes
Glycemic control
MASLD / fatty liver
Hepatic fat
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Molecular profile
Key studies
Triple Hormone Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Jastreboff AM, et al.
In a Phase 2 trial (338 adults), once weekly retatrutide produced up to ~24% mean body weight reduction at 48 weeks, among the largest losses reported for a pharmacotherapy.
Evidence, safety & status
Claimed benefits & evidence
The best evidenced compound on the storefront by a wide margin. Eli Lilly's Phase 3 TRIUMPH (obesity) and TRANSCEND (diabetes) programs are large and double blind. TRANSCEND-T2D-1 (537 adults, The Lancet 2026) met its primary endpoint with HbA1c reductions up to ~2.0%; TRIUMPH-1 (obesity, reported May 2026) reported average weight loss ~28% at 12 mg. Still investigational.
Safety & dangers
AE profile consistent with the GLP-1 class, predominantly dose dependent GI (nausea, vomiting, diarrhea, constipation). A retatrutide specific dysesthesia (altered skin sensation) signal is worth watching. The glucagon arm warrants glycemic and heart rate monitoring. Gray market use without titration or monitoring is especially hazardous, this is an investigational pharmaceutical with drug level effects, not a 'wellness peptide.'
Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2; pregnancy; history of pancreatitis; caution with other glucose lowering agents.
Regulatory status
Not yet FDA approved as of mid-2026, investigational, Phase 3 ongoing. Any retatrutide sold now is pre approval (gray market or compounded), with full quality risk. WADA: prohibited (S0 + GLP-1 class).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
For research use only
For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.